Bright Minds Biosciences Inc. (DRUG) Institutional Ownership

Ownership Summary

Bright Minds Biosciences Inc. (NASDAQ:DRUG) appears in 9 institutional 13F filings for the quarter ending June 2023.

• These investors held 15.2% of outstanding shares in June 2023, down from 15.4% in March 2023.
• Their total shares held in DRUG increased 11.24% from the prior quarter, while the number of investors in Bright Minds Biosciences decreased 18.18% year over year.
• Of these 9 holders, 4 added to their stakes in Bright Minds Biosciences, 2 trimmed positions, and 3 made no changes.
• Institutional investors collectively held 573.73K shares in Bright Minds Biosciences as of June 2023, up by 57.95K shares quarter on quarter, and up 86.01K shares year over year.
• As of June 30, 2023, Janus Henderson Group Plc held the largest stake in Bright Minds Biosciences with 2.57Mn shares, accounting for 68.1% of total shares outstanding.
• Top purchasers of DRUG stock for the quarter ending June 2023 included Janus Henderson Group Plc (1.41Mn), Vestal Point Capital, LP (492.32K), DEERFIELD MANAGEMENT COMPANY, L.P. (283.0K), RA CAPITAL MANAGEMENT, L.P. (265.0K), BlackRock, Inc. (227.89K).
• The largest sales of DRUG for the quarter ending June 2023 came from MILLENNIUM MANAGEMENT LLC (141.6K), PERCEPTIVE ADVISORS LLC (71.75K), SUPERSTRING CAPITAL MANAGEMENT LP (33.97K), BNP PARIBAS FINANCIAL MARKETS (24.1K), Goldman Sachs Group Inc (22.72K).
• Per Business Quant data, the top 10 holders of Bright Minds Biosciences for the quarter ending June 2023 are Janus Henderson Group Plc (2.57Mn), Cormorant Asset Management, LP (1.06Mn), BlackRock, Inc. (621.93K), Vivo Capital, LLC (557.17K), BRAIDWELL LP (539.71K), ADAGE CAPITAL PARTNERS GP, L.L.C. (495.74K), Vestal Point Capital, LP (492.32K), DRIEHAUS CAPITAL MANAGEMENT LLC (432.52K), PERCEPTIVE ADVISORS LLC (377.54K), BALYASNY ASSET MANAGEMENT L.P. (297.16K).